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New Guidelines
In June 2013, the WHO issued new
guidelines for antiretroviral treatment
(ART). The guidelines substantially ex-
pand eligibility for ART, recommending
initiation at CD4 cell counts #500 cells/ml
instead of at #350 cells/ml. For HIV-
positive patients with active tuberculosis
(TB) or hepatitis B, HIV-infected partners
in serodiscordant couples, pregnant and
breastfeeding women, and children youn-
ger than five years of age, ART is to begin
immediately upon HIV diagnosis and
irrespective of CD4 cell count or clinical
stage [1].
While there has been vigorous debate
regarding the strength of the evidence
underlying some of the recommendations
included in the WHO guidelines [2], as in
the past, these guidelines are likely to be
influential. Sub-Saharan African countries
usually adopt WHO recommendations as
national policies within a few years, while
others anticipate them. For example, the
WHO recommended ART initiation at
CD4 cell count #350 cells/ml in 2010,
when Ghana, Sierra Leone, Lesotho,
Rwanda, Djibouti, Niger, and Tanzania
had already adopted this standard; Guin-
ea, Kenya, Malawi, South Africa, Swazi-
land, Zimbabwe, and Botswana followed
within two years. Even before WHO’s
latest guideline change, Malawi and Zam-
bia committed to providing lifelong ART
to all pregnant and breastfeeding women;
Rwanda’s national guidelines recommend
ART for all HIV-infected partners in
serodiscordant relationships. Zimbabwe
has declared that it will start initiating
HIV-infected patients on ART when their
CD4cellcountsdropbelow500 cells/ml[3];
Zambia, Namibia and Swaziland are in the
process of adopting the new ART initiation
threshold for the general population; and
South Africa is deliberating when to follow
suit.
Given sufficient resources, adoption of
the new WHO guidelines will likely lead to
further reductions in the burden of HIV in
countries severely affected by the epidem-
ic. But there is also an unintended negative
side-effect. The large-scale HIV Treat-
ment-as-Prevention (TasP) trials planned
or underway in sub-Saharan Africa are
now at risk. The knowledge that the trials
would generate would likely be critical to
ensuring long-term government and donor
enthusiasm for devoting extensive resourc-
es to HIV treatment. The case for such
resource commitments would be much
stronger if it were proven that HIV
treatment can indeed substantially reduce
HIV incidence in general populations in
sub-Saharan Africa. We discuss policy
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Summary Points
N Randomized controlled trials of HIV treatment-as-prevention (TasP) are
necessary to establish TasP effectiveness in general populations in sub-Saharan
Africa.
N WHO’s new HIV treatment guidelines inadvertently threaten the ongoing TasP
trials in sub-Saharan Africa because they recommend substantially expanded
HIV treatment eligibility.
N Historically, countries in the region have adopted WHO HIV treatment
guidelines as national policies within two years of guideline publication. This
time pattern is also emerging in the case of the new WHO guidelines: several
sub-Saharan African countries are currently in the process of adopting the
guidelines. If the countries hosting the TasP trials adopted the new WHO
guidelines within the coming years, the trials in their original designs would
become ethically impermissible, because they offer HIV treatment in the control
arms under the more restrictive eligibility rules that are the current standard of
care in the region. But offering the WHO-recommended expanded treatment
standards in the control arms would likely render the trials underpowered.
N Fortunately, there are ways to generate rigorous evidence on TasP even if the
new WHO guidelines are adopted. They include pooling results across trials and
securing the agreement of governments to scale up expanded ART eligibility to
communities in random order.
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WHO guidelines while ensuring that we do
not lose the historic opportunity to learn
whether TasP works where it matters most.
The TasP Trials
In addition to male medical circumci-
sion, prevention of mother-to-child trans-
mission (PMTCT) and pre-exposure pro-
phylaxis (PrEP) [4], recent optimism for an
‘‘AIDS-free generation’’ has rested in large
parts on the promise of TasP [5]. In TasP,
ART is provided to all HIV-infected
individuals upon HIV diagnosis, irrespec-
tive of CD4 cell count or clinical stage.
The hope is that the suppression of viral
loads in nearly everybody who is infected
will prevent most onward transmissions of
HIV. It has been shown that TasP nearly
eliminates HIV transmissions in one par-
ticular population: HIV-uninfected part-
ners in stable HIV-serodiscordant couples
whohave disclosedtheir HIVstatusto each
other and are willing to jointly participate
in an individually randomized controlled
clinical trial [6]. However, TasP’s potential
for curbing the HIV epidemic in general
populations with many different relation-
ship types and different levels of care
delivery and support remains an untested
hypothesis, notwithstanding strong evi-
dence on the preventive effect of ART
under current guidelines from a popula-
tion-based cohort study in rural South
Africa [7] as well as results from several
mathematical models predicting large TasP
effects on HIV incidence [8, 9,10].
To test the hypothesis that TasP can
substantially reduce HIV incidence in
general populations in sub-Saharan Africa,
several multi-year cluster-randomized con-
trolled trials are currently on-going or
getting under way in South Africa, Zam-
bia, and Botswana [11–13]. These trials
have been funded with many tens of
millions of dollars by the US National
Institutes of Health (NIH), the Centers for
Disease Control (CDC), the Bill & Me-
linda Gates Foundation, the French
Agence National de Recherches sur le
Sida et les He ´patites Viral (ANRS), and
others. The trials are designed to compare
the effect of TasP on HIV incidence
against the practice of starting ART only
in people with CD4 cell count #350 cells/
ml or advanced clinical stages.
How Adoption of WHO
Guidelines Would Jeopardize
the TasP Trials
If host countries adopt the new WHO
threshold of CD4 cell count #500 cells/
ml, current ethical standards will require
that care given to patients enrolled as
controls in the TasP trials be based on this
threshold as well. For two decades,
controversy has surrounded the standard
of care offered to patients enrolled as
controls in clinical trials in low-income
countries. Opinions range from, at one
extreme, the World Medical Association’s
Declaration of Helsinki, according to
which new interventions ‘‘…must be
tested against those of the best current
proven intervention…’’ (132) to those who
would require only that care for controls
meet the standard prevailing at the test site
[14]. None of the parties to the dispute,
however, has defended provision of care
inferior to the care available locally. That is
what was offered to trial subjects in the
infamous Tuskegee Syphilis study and is
one basis for its odious reputation.
The level of care for participants in the
control arms of the TasP trials cannot be
inferior to the care available locally. But
the TasP trials were designed and powered
assuming a CD4 cell count #350 cells/ml
threshold. If sub-Saharan countries soon
adopt the CD4 cell count #500 cells/ml
threshold, the difference between the care
provided in the TasP trials’ intervention
and control arms will probably be too
small to detect statistically significant
effects on HIV incidence. According to
recent data, expanding general ART
eligibility to patients at CD4 cell count #
500/ml would roughly halve the number of
people who are treatment-eligible in the
TasP trials’ intervention arms but ineligi-
ble in the control arms [15]. Moreover,
the new WHO guidelines make all HIV-
infected partners in serodiscordant rela-
tionships treatment-eligible regardless of
CD4 cell count. About three-quarters of
adults in sub-Saharan Africa report being
in stable cohabiting relationships [16–18],
and up to half of HIV-infected Africans in
stable relationships have an HIV-uninfect-
ed partner [19]. Adoption of the new
WHO guidelines thus would likely reduce
by at least two-fifths the number of people
who are treatment-eligible in the TasP
trials’ intervention arms but not in their
control arms. Where the new guidelines
are implemented, the difference in HIV
incidence between the TasP trials’ inter-
vention and control arms will likely be
reduced to a fraction of the difference
under which the trials were originally
powered. In this situation, data safety
and monitoring boards (DSMBs) or policy
makers may stop the trials; and even if
they don’t, the trials will likely fail in
their primary aim to establish the effec-
tiveness of TasP in general populations in
sub-Saharan Africa because of insufficient
power. With adoption of the new WHO
guidelines as local standard now looming
in the countries in which TasP trials take
place, the premature or inconclusive end
of the trials in their present form is thus
predictable, raising the difficult question
whether and how the trials should contin-
ue. Similar complications may arise for
trials testing other ART-based HIV pre-
vention strategies, such as interventions to
prevent mother-to-child transmission.
Here we focus on the case of TasP trials
in the general population.
Do We Still Need TasP Trials?
Policy makers, trialists, and members of
the HIV community may wonder: Do we
still need trials, now that ART initiation
immediately after HIV diagnosis is con-
sidered so effective and safe for the
individual patient’s health that, since
2012, it is the United States standard of
care [20]? The purpose of the trials,
however, is not to establish the effective-
ness or safety of early ART for already
infected individuals, but to determine
whether comprehensive TasP will reduce
HIV incidence at the population level. A
positive trial result would justify large
increases in ART investment and TasP
implementation in the countries worst-
affected by the HIV epidemic.
If the incidence of HIV were to
plummet wherever the new WHO guide-
lines are adopted, few would lament that
TasP had not been validated in random-
ized control trials. However, if incidence
continued to be high in some places after
guideline adoption, effective HIV preven-
tion strategies would remain necessary and
yet we would not know whether TasP
qualifies for this purpose. Absent trial data,
TasP strategies might be wrongly discred-
ited, with potential long-term damage to
our ability to raise funds for the routine
implementation of TasP, because govern-
ments and donors may not be willing to
invest in expensive intervention strategies
if their effectiveness has not been proven.
Defensible TasP Trials?
How can rigorous scientific evidence on
TasP effectiveness be obtained even as
sub-Saharan countries are adopting the
new guidelines? We present four alterna-
tives. The first two are clearly unsatisfac-
tory, in our view. The last two are
tentative proposals that might deserve
consideration. Even if none is satisfactory,
they may prompt other proposals and
serve as a starting point for an important
debate.
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The trials could continue on their
present course without asking controls
to accept care below the local standard
if policy makers in host nations de-
ferred adoption of the new WHO
guideline until the trials have been
completed. However, assuming that
the new WHO standard has substantial
therapeutic value, the population
health impact of such a move would
make it clearly unethical.
2. Expanding the trials: The problem of
underpowered trials could, in theory,
be overcome either by greatly expand-
ing the number of trial sites and
participants or by lengthening the
period of observation substantially
beyond the originally planned dura-
tion. But it is unlikely that either of
these options is feasible. At many tens
of millions of dollars, the cost of the
trials is already immense, and funding
has been secured only with great effort.
To ensure that the trials are not
underpowered even as control arms
are offered ART starting at CD4 cell
counts #500/ml and treatment differ-
ences between intervention and control
arms shrink, the scale and, accordingly,
the budgets would likely have to be
doubled or tripled. This is unlikely to
happen.
3. Pooling results: Considered separately,
the three trials that are currently under
way in South Africa, Zambia, and
Botswana will likely become under-
powered as the new WHO guidelines
are adopted and individuals in the
control arms are offered ART under
expanded eligibility. Jointly, however,
the trials might remain sufficiently
powered to detect significant incidence
effects of TasP. Because of differences
in trial design, it is currently unclear
whether the results of the trials can be
pooled. It is also uncertain whether the
potential power gains from pooling will
be sufficient to fully compensate for the
expected power reductions following
adoption of the new WHO guidelines.
These questions should be urgently
answered.
4. Turning the trials into cluster-randomized
scale-ups: Even when governments
commit to implementing the #500
CD4 cell count threshold, communi-
ties will know from experience that a
national decision to adopt a new and
higher standard of care is but the first
step. In many communities, it may
take many years before universal or
near-universal access to care at the
new standard is achieved. Indeed,
even after a decade of vigorous
ART scale-up in sub-Saharan Africa,
WHO estimates that about 40% of
currently eligible patients in the sub-
continent are still not receiving ART
[21]. In this proposal, the schedule for
the gradual scale-up of the new WHO
guidelines (or even of TasP) would be
randomly assigned, creating the op-
portunity for a stepped-wedge ran-
domized controlled study. The overall
pace of the scale-up could remain
unaffected. A key to scientific validity,
randomization may also be ethically
preferable to standard political decision-
making on who receives the new
standards first and who later. Random-
ization is valued for its impartiality [22–
24], and it gives patients in remote rural
areas, where rollout is more expensive
and often comes last, an equal chance
for ART [24,25]. Such coordination
between trialists and health policy-mak-
ers is a relatively new concept, but there
have been some successful precedents
[26].
Conclusions
HIV TasP is one of our best current
hopes for bringing the era of HIV to a
close. Strong causal evidence that TasP
works in general populations in sub-
Saharan Africa, where the HIV epidemic
is at its most severe, is still outstanding.
This evidence, however, will be critical for
ensuring that countries and donors will
continue to provide the resources that are
necessary to deliver near-universal ART
coverage over the coming decades. Three
large TasP trials that would generate this
evidence are currently underway in sub-
Saharan Africa. The adoption of the new
WHO treatment guidelines, which recom-
mend substantially expanded ART eligi-
bility, would render the trials in their
original designs unethical. Discussion is
needed in order to allow some format of
TasP trials to take place without delaying
the adoption of the new WHO guidelines.
We have mentioned several policy alter-
natives—some clearly unsatisfactory from
an ethical or practical viewpoint, others
more promising—in the hope of starting
that discussion. More broadly, the case of
the TasP trials and the WHO treatment
guidelines is an example of the often
difficult interaction between health policy
and the scientific enterprise. Governments
and international organizations demand
strong evidence for policy formulation, but
are commonly also compelled to act while
evidence remains incomplete. As in the
case of TasP, careful study design and
well-coordinated policy implementation
may allow major policy initiatives to go
ahead without conclusive evidence, while
preserving our ability to generate the
evidence and, in doing so, ensuring the
long-term success of the policies.
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